MicroStrategy — now operating under the name “Strategy” (Nasdaq: MSTR/STRK) — has priced a new preferred stock offering that ...

In the study, ACP-711 was safe and generally well tolerated across all dosing cohorts. There were no serious adverse events, and all participants completed the study. Most adverse events were mild.